This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

This study has been terminated.
(Poor recruitment of fast and slow acetylators)
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: March 24, 2009
Last updated: September 15, 2009
Last verified: September 2009
The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.

Condition Intervention Phase
Healthy Drug: Talampanel (non-radiolabeled), [14C] Talampanel Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • To determine the mass balance of [14C]-talampanel. To characterize the metabolism of [14C] talampanel in plasma, feces, and urine. To assess the pharmacokinetics (PK) of total radioactivity, talampanel, and N-acetyl talampanel. [ Time Frame: 6-9 days ]

Secondary Outcome Measures:
  • To explore the effect of N-acetyltransferase 2 (NAT2) genotype on the PK and metabolism of [14C] talampanel. To further assess the safety and tolerability of talampanel. [ Time Frame: 6-9 days ]

Estimated Enrollment: 10
Study Start Date: May 2009
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Slow and rapid N-acetyl transferase genotypes Drug: Talampanel (non-radiolabeled), [14C] Talampanel
50 mg capsule single dose
Other Name: TV-7600


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males, between 18 and 55 years of age, inclusive
  • Body Mass Index range 18.0 to 30.0 kg/m2, inclusive
  • Have NAT2 slow or rapid acetylator genotype
  • In good health as determined by the investigator
  • Negative test for selected drugs of abuse at screening
  • Negative screens for Hepatitis B, Hepatitis C and HIV
  • Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge
  • Able to comprehend and willing to sign an Informed Consent Form
  • Have 1 to 2 bowel movements per day

Exclusion Criteria:

  • Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
  • History of stomach or intestinal surgery or resection
  • History or presence of an abnormal ECG,
  • History of clinically significant alcohol or drug use within 1 year prior to Check-in
  • Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in
  • Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in
  • Use of any drugs which may interact with the study drug within 30 days prior to Check-in
  • Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in
  • Use of any prescription medications/products within 14 days prior to Check in
  • Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in
  • Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in
  • Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in
  • Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion
  • Receipt of blood products within 2 months prior to Check-in
  • Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00868361

United States, Wisconsin
Covance Clinical Pharmacology Inc.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Teva Pharmaceutical Industries
Principal Investigator: Nicholas M Siebers, MD Covance
  More Information

Responsible Party: Siyu Liu, M.D., Ph.D., Vice President, Innovative Research and Development and Head of Global Clinical Operations Identifier: NCT00868361     History of Changes
Other Study ID Numbers: TAL-MB-100
Study First Received: March 24, 2009
Last Updated: September 15, 2009

Keywords provided by Teva Pharmaceutical Industries:
Mass Balance
Healthy Volunteers processed this record on September 21, 2017